Savara Inc. is also under scrutiny, facing a class action lawsuit for the period between March 7, 2024, and May 23, 2025, with the deadline for lead plaintiff motions set for November 7, 2025. Allegations indicate that critical information regarding the company's product, MOLBREEVI, was not disclosed adequately, jeopardizing its FDA approval timeline and investor confidence.